Immediate Impact

67 standout
Sub-graph 1 of 20

Citing Papers

Role of SLC7A11/xCT in Ovarian Cancer
2024 Standout
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
2023 Standout
2 intermediate papers

Works of Allison E. Axtell being referenced

Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment
2010
Platinum/taxane‐based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma
2009

Author Peers

Author Last Decade Papers Cites
Allison E. Axtell 590 707 384 13 873
Tom Manolitsas 773 561 267 27 1.0k
R.E. Bristow 371 645 449 9 855
Stephen Dobbs 542 963 639 16 1.1k
H. Dahan 668 371 339 24 1.2k
Maria Giovanna Salerno 493 425 330 26 830
Daniel S. Metzinger 627 572 332 33 1.0k
Helena O’Flynn 454 324 547 23 1.1k
F McGlynn 398 353 439 17 881
G Bratina 409 734 280 24 1.0k
J A Blessing 718 709 392 17 1.1k

All Works

Loading papers...

Rankless by CCL
2026